[Home](https://github.com/mm80843/T3.5/blob/main/docs/index.md) >> Class: [Risk](https://github.com/mm80843/T3.5/tree/main/docs/Risk/index.md) >> Individual ID:PBN__Risk_1158 

# __Lack of access to pharmaceutical interventions__

## Category to which it belongs

* [The challenges include reduced surgical education, loss of control, limited diagnostics, slow drug development, inadequate patient monitoring, and lack of drug therapy options.](https://github.com/mm80843/T3.5/blob/main/docs/PBNCategory/PBN__PBNCategory_100.md)

## Closest similar item

* [Lack of accessibility of pharmaceutical interventions in developing countries](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_727.md)
* [Insufficient non-pharmaceutical interventions](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_1603.md)
* [Ineffective non-pharmaceutical interventions](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_1490.md)
* [Lack of effective pharmaceutical response](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_1602.md)
* [Lack of drug therapy options](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_1146.md)
* [Lack of healthcare access](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_3194.md)
* [Lack of access to healthcare services](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_2503.md)
* [Lack of effective drugs](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_2724.md)
* [Impact on healthcare systems and pharmaceutical industry](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_1812.md)
* [Shortage of medical equipment and medication](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_703.md)

## Description of the risk

Developing countries may not have timely access to antiviral medicines and vaccines

## Is the risk affecting GBN scales

* [No](https://github.com/mm80843/T3.5/blob/main/docs/RiskGBN/PBN__RiskGBN_0.md)

## Type of the risk

* [physical](https://github.com/mm80843/T3.5/blob/main/docs/RiskHealth/PBN__RiskHealth_0.md)

## Type of impact of the risk (according to ISO37100)

* [Biodiversity and ecosystem services](https://github.com/mm80843/T3.5/blob/main/docs/RiskISO/PBN__RiskISO_Purpose_4.md)

## Type of purpose of the risk (according to ISO37100)

* [Attractiveness](https://github.com/mm80843/T3.5/blob/main/docs/RiskISO/PBN__RiskISO_Impact_9.md)

## Mitigations of this risk

* [Focus on non-pharmaceutical interventions, prioritize distribution to countries in need](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_1610.md)

## Name of the risk

Higher morbidity and mortality rates in affected populations

## Stakeholders who can mitigate this risk

* [governments](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_47.md)
* [pharmaceutical companies](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_124.md)
* [international organizations](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_242.md)

## Articles mentionning the risk

* [An e-mental health intervention to support burdened people in times of the COVID-19 pandemic: CoPE It](https://github.com/mm80843/T3.5/blob/main/docs/Article/PBN__Article_209.md)

## People affected by this risk

* [developing countries](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_223.md)

## Technologies linked to the risk


## Property: has_RiskType

* [technological](https://github.com/mm80843/T3.5/blob/main/docs/RiskType/PBN__RiskType_5.md)

